Mala K. Maini

A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection

HBV shows different levels of adaptation to HLA class I-associated selection pressure correlating with markers of replication

New Approaches to Chronic Hepatitis B

The scientific basis of combination therapy for chronic hepatitis B functional cure

Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS

Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

SARS-CoV-2–specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies

Immunotherapies for hepatocellular carcinoma

Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection

The human liver microenvironment shapes the homing and function of CD4 ⁺ T-cell populations

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes

Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients

Human Liver Memory CD8+ T Cells Use Autophagy for Tissue Residence

ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome

A global scientific strategy to cure hepatitis B

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient